Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Prof. Oliver Sartor
Mayo Clinic, Rochester, MN, USA
Prof. Oliver Sartor is director of radiopharmaceutical trials and professor of medicine, urology and oncology in the Department of Medical Oncology at the Mayo Clinic, Rochester, MN, USA. read more
His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). After serving as the associate dean for oncology and medical director of the Tulane Cancer Center, he moved to the Mayo Clinic in April 2023, where he now works in a multidisciplinary environment intersecting with urology, nuclear medicine and medical oncology. He serves as the vice-chair of the genitourinary cancer committee of NRG Oncology, a national cancer research group focused on radiotherapies. Past endeavours have included terms as a member of the NCI Board of Scientific Counselors (Clinical Sciences and Epidemiology) and as a faculty member at the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute at Harvard. He has also served as past editor-in-chief of the peer-reviewed journal Clinical Genitourinary Cancers.
He has published over 500 manuscripts and led or co-led multiple national and international clinical studies, including multiple phase III studies in prostate cancer (samarium-153 ethylene diamine tetra methylene phosphonate [EDTMP], cabazitaxel, radium-223 and lutetium-177-prostate specific membrane antigen [PSMA]-617). In addition to therapeutic studies, he has long been involved with translational and scientific studies in patients with prostate cancer. The issues related to prostate cancer have many complex genetic and non-genetic changes and, in these projects, he has been a catalyst for helping to understand how prostate cancer develops and progresses. He has lectured widely, and at the last count had given invited lectures in 33 countries.
Prof. Oliver Sartor discloses: Advisory board or panel fees from ArtBio, Clarity, Convergent and NorthStar. Consultant fees from Advanced Accelerator Applications, a Novartis company, Amgen, ArtBio, Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Clarity, Convergent, EMD Serono, Fusion, Genzyme, Hengrui, Isotopen Technologien München, Janssen, Merck, Myovant, Myriad, Noria Therapeutics, NorthStar, Novartis, Point BioPharma, Pfizer, Ratio Therapeutics, Sanofi, Telix and Theragnostics. Grants/research support from Advanced Accelerator Applications, a Novartis company, Amgen, AstraZeneca, Bayer, Invitae, Janssen, Lantheus, Merck and Sanofi. Stock/shareholder (self-managed) AbbVie, ArtBio, Cardinal Health, Convergent, Eli Lilly, Fusion Pharmaceuticals, Point Biopharma, Ratio Therapeutics, Rayze, Telix and United Health Group.
Prof. Francesco Ceci
European Institute of Oncology, IRCCS, Milan, Italy
Prof. Francesco Ceci is the director of the Division of Nuclear Medicine at the European Institute of Oncology, Scientific Institute for Research, Hospitalization and Healthcare, Milan, Italy, and professor of nuclear medicine in the Department of Oncology and Hemato-Oncology at the University of Milan. read more
His clinical focus is in the field of molecular imaging and radioligand therapy. His clinical research activity concerns prostate-specific membrane antigen (PSMA) positron emission tomography and lutetium-PSMA therapy in male genitourinary tumours, and clinical applications in the field of radiomics and artificial intelligence in the main oncological and onco-haematological pathologies.
He is the author of numerous publications in international scientific journals and actively collaborates with many research centres and universities in Europe and the USA.
Prof. Francesco Ceci discloses: Advisory board or panel fees from Novartis and Telix (relationships terminated). Consultant fees from Curium and Novartis (relationships terminated). Other financial or material support from Bayer, Curium, Janssen Oncology, Novartis, Radmetrix and Telix (relationships terminated).
Dr Heather Jacene
Dana-Farber Cancer Institute, Boston, MA, USA
Dr Heather Jacine is a senior physician and the clinical director of nuclear medicine at the Dana-Farber Cancer Institute, Boston, MA, USA. She is also the associate programme director at Brigham and Women’s Joint Program in Nuclear Medicine and associate professor of radiology at Harvard Medical School. read more
She completed her residency and fellowship in nuclear medicine and positron emission tomography/computed tomography (PET/CT) at Johns Hopkins University, Baltimore, MD.Â
Dr Jacene has served as a director on the American Board of Nuclear Medicine and on numerous committees within the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Her current positions include
chair of the Scientific Program Committee and chair of the Quality of Practice Domain for the SNMMI.
Dr Jacene has vast expertise in the interpretation of oncology PET/CT scans and in treating various tumour types with radiopharmaceutical therapy. She extends this expertise to her research, which focuses on the use of fluorodeoxyglucose PET/CT and other novel tracers for characterizing and monitoring the response of cancer to therapy, as well as the use of radiopharmaceutical therapy.
She has authored over 85 peer-reviewed publications, as well as many reviews and book chapters.
Dr Heather Jacene discloses: Advisory board or panel fees from Spectrum Dynamics Medical Ltd. Consultant fees from Blue Earth Diagnostics. Grant/research support fees from GTx and Siemens.
